Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study
about
Hepatitis B vaccine antibody response and the risk of clinical AIDS or deathIdentification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohortA comparison of HAART outcomes between the US military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS)Combining epidemiologic and biostatistical tools to enhance variable selection in HIV cohort analyses.HIV outcomes in Hepatitis B virus coinfected individuals on HAARTThe VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSHepatitis B vaccine responsiveness and clinical outcomes in HIV controllers.Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.Recent trends in early stage response to combination antiretroviral therapy in Australia.Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort.Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness.D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.High Initial HIV/AIDS-Related Mortality and -Its Predictors among Patients on Antiretroviral Therapy in the Kagera Region of Tanzania: A Five-Year Retrospective Cohort StudyThe impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.Modelling the impact of antiretroviral therapy on the epidemic of HIVHospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study.Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaFactors associated with 10 years of continuous viral load suppression on HAART.Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapyResults of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care.Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapyRace/ethnicity and HAART initiation in a military HIV infected cohort.Nationally representative prevalence estimates of gay, bisexual, and other men who have sex with men who have served in the U.S. military.Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures.Place-Based Predictors of HIV Viral Suppression and Durable Suppression Among Men Who Have Sex With Men in New York City.Inference for Surrogate Endpoint Validation in the Binary Case.Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.Antiretroviral changes during the first year of therapy.Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults.
P2860
Q28730976-C21AE27B-B85C-46B8-8473-1B1AD6625FAAQ30485790-BB173397-98BB-4F92-8489-F92E71DD4259Q30486127-FA4FEBE2-F595-495E-B9B0-32D06F4700B0Q31149210-946A8F86-E150-4D6B-8DE5-3CD7BA846AACQ33665820-237576F8-8F32-4126-8F02-4B22D61AEBB0Q33881303-5459CC96-6EF4-491C-BBE1-3B60CA74132BQ33916321-7078DB68-A42E-41BC-A655-6650E22CCE31Q34075566-1911E6F1-4B53-4155-80BA-9F09CAA00633Q34153838-4E8E9DC3-36C9-406C-9922-85408E560F98Q34289433-88FCA69A-D808-449E-B3C9-B3A67D20AA52Q34569335-FFFFA355-EA2E-4DEE-8357-DF3257460D57Q34666498-57E2FC34-F818-46D7-A68C-8A80D84D8859Q35057326-B10486AF-D104-4C50-9D06-7B9C1B91F014Q35213754-8D0AA7B6-602D-426C-AC80-0736AA527CE0Q35557314-2E594436-EECF-4D27-9D10-0076792D3877Q35576220-E75DE2FD-624E-4BCB-8767-CD533E242172Q35873534-709DAF2D-A2FF-427C-819F-4DE7087C7712Q35959321-2F742536-8FDC-452C-84E4-956F51429F5EQ35992200-B2D948E9-5330-42D9-8F56-56457A12F74EQ36220774-50E9D6F9-64B2-4812-B86B-7F8E1EB8CE40Q36428784-E4BB8BCA-E98C-4301-9084-44BE22C55B55Q36486234-11976284-8BCE-47E9-B1C6-83AB4243BBA9Q36665336-B2C99897-E401-4CA6-8E36-5678D74D0C11Q36715193-1AFD613C-D704-4D00-9F4E-6F76D9119938Q37033512-03BF290E-7839-44F7-A7F4-4FBC2F15DFCCQ37118025-2C5545FD-C616-48FB-8D61-B56E410C5910Q37207042-BD669F69-B43D-40AC-8B1D-FFDCE054C740Q37355795-0775C2CA-57D8-45E7-A693-8D7BABA0EBD7Q37523341-C3CE38EA-AF12-4EC8-AC31-BF05F7BB56A3Q37563963-7EAFDB3E-6AE5-490D-AB75-5429C41DBA00Q37580896-93A36511-8D7F-45F2-B8C8-29DDE60D83BAQ38649223-1CC9DDA1-1FAA-4F18-B9A0-D6A4730C4C37Q39670782-837E9E2A-6827-4362-AA0E-161EA595A2BAQ40147303-A850642C-13DC-4DF2-8567-0E12539A0DD8Q41524577-55C0643A-9A5F-4D67-A062-56710B3D6263Q41600432-5EFB49E9-23BC-40DD-AF4B-B43422456383Q41924662-528CE680-E93D-4DAD-87A7-E44E19C514FBQ42262381-F36D223E-3362-4B3F-964B-76B05E68F926Q46811196-25785086-9BE5-4CA7-977B-3112A8EB8179Q55169028-2681EFFE-954C-4414-A96E-3DA367CD9F33
P2860
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Outcomes of highly active anti ...... tary HIV Natural History Study
@ast
Outcomes of highly active anti ...... tary HIV Natural History Study
@en
type
label
Outcomes of highly active anti ...... tary HIV Natural History Study
@ast
Outcomes of highly active anti ...... tary HIV Natural History Study
@en
prefLabel
Outcomes of highly active anti ...... tary HIV Natural History Study
@ast
Outcomes of highly active anti ...... tary HIV Natural History Study
@en
P2093
P2860
P50
P356
P1476
Outcomes of highly active anti ...... tary HIV Natural History Study
@en
P2093
Alan Lifson
Amy C Weintrob
Glenn W Wortmann
Greg A Grandits
Helen Chun
Infectious Disease Clinical Research Program HIV Working Group (IDCRP)
Jason F Okulicz
Michael L Landrum
Nancy Crum-Cianflone
Robert J O'Connell
P2860
P2888
P356
10.1186/1742-6405-7-14
P577
2010-05-27T00:00:00Z
P5875
P6179
1017363446